Enlivex up after Greece allows sepsis treatment trial

Enlivex

07/12/2021 15:54

** U.S.-listed shares of Israel-based drug developer Enlivex
Therapeutics  ENLV.O  rise 1.4% to $6.85 
    ** ENLV says Greece's National Organization of Medicines has
allowed expansion of co's mid-stage clinical trial testing
experimental therapy for pneumonia-associated sepsis, Allocetra,
to sites in the country  urn:newsml:reuters.com:*:nGNX2B9q6S
    ** Sepsis is a condition that occurs when the body's
response to an infection damages its own tissues
    ** Decision was based on the review of co's preclinical and
clinical data, study design and manufacturing process - ENLV
    ** Trial, which has multiple sites currently open for
enrollment in Israel and was recently cleared to expand into
Spain, is expected to enroll 120 to 160 patients
    ** Interim results from mid-stage trial are expected in H1
of 2022, and top-line data is expected by end-2022
    ** Stock down ~19% YTD 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))